This study is in progress, not accepting new patients

Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies

a study on Parkinson's Disease AADC Deficiency

Summary

Eligibility
for people ages 40 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Chadwick Christine

Description

Summary

An extension study for participants who have completed a prior VY-AADC01 clinical study

Official Title

An Observational, Long-Term Extension Study for Participants in Prior VY-AADC01 Clinical Studies

Keywords

Parkinson's Disease, Parkinson's Disease (PD), Gene Therapy, Motor Fluctuations, Neurosurgery, NBIb-1817, Aromatic L-Amino Acid Decarboxylase, Levodopa, Dopamine, AADC, DDC, AAV2-hAADC, AAV, VY-AADC, Parkinson Disease

Eligibility

You can join if…

Open to people ages 40 years and up

  1. Completed participation in the PD-1101 or PD-1102 clinical study of VY-AADC01 gene therapy

You CAN'T join if...

None

Locations

  • UCSF
    San Francisco California 94143 United States
  • Ohio State University
    Columbus Ohio 43210 United States

Lead Scientist at UCSF

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Neurocrine Biosciences
ID
NCT03733496
Study Type
Observational
Participants
About 14 people participating
Last Updated